Farmas USA

mola la bitbucket !

EXEL

Aprobación en UE para HCC

Exelixis’ Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) Tablets for the Treatment of Hepatocellular Carcinoma in Adults Previously Treated with Sorafenib

– EC approval triggers $40 million milestone payment to Exelixis under Collaboration Agreement with Ipsen –

– Exelixis’ supplemental New Drug Application for CABOMETYX for previously treated advanced HCC currently in review with the U.S. Food and Drug Administration –

http://ir.exelixis.com/phoenix.zhtml?c=120923&p=irol-newsArticle&ID=2377258

A comprar como posesos . hahahaha

Vamooooooossss!!! Capaces son de cascarle otro -5%

EXEL

Igual "la subida" fue ayer, que con la que caía se mantuvo en verde...

Por cierto, se han largado los Baker Bros, sold out. 510k cromos

Veo que han aumentado en ACAD 1,2mill de acc y en NVAX le han metido 4,7 mill de cromos a la saca. Hoy último día para dar a conocer los movimientos de Q3 de los Institucionales.

Los Baker Brothers
https://www.sec.gov/Archives/edgar/data/1263508/000114420418059891/xslForm13F_X01/infotable.xml

ARNA

Arena Pharmaceuticals and United Therapeutics Announce Global License Agreement for Ralinepag

- Arena will receive $800M upfront, and is eligible to receive low double-digit tiered royalties, plus up to $400M in milestone payments
- United Therapeutics will receive exclusive, worldwide rights to ralinepag - a potential best-in-class agent for the treatment of pulmonary arterial hypertension
- Arena to host conference call and webcast today at 8:30

http://invest.arenapharm.com/news-releases/news-release-details/arena-pharmaceuticals-and-united-therapeutics-announce-global